Researchers have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers.
Read MoreAeterna Zentaris Inc announced a collaborative study with Almac’s Diagnostics division for the company’s doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108.
Read MoreThomas Jefferson University in Philadelphia, PA and NuView Life Sciences have entered into an exclusive licensing agreement for advancing the development of a new molecular imaging compound which identifies genomic expressions linked to prostate cancer.
Read MoreResearchers believe that genetics and traditional screening methods could play a role in predicting the risk of prostate cancer in younger men.
Read More
This month’s cover story on mass spectrometry for the clinical lab is the first CLP has published on this topic, but I don’t believe it will be our last. According to sources at the FDA and the National Cancer Institute’s proteomics prog
Read More